Respiratory Distress Syndrome, Adult

Respiratory·MeSH: Respiratory Distress Syndrome

Prevalence

30.0 / 100K

6 drugs in development·2 companies·3 clinical trials

Drug Pipeline by Phase

Phase 2(4)

Drug	Company
Cell Reconstitution Media	UNITED THERAPEUTICS Corp (UTHR)
Human Mesenchymal Stromal Cells	UNITED THERAPEUTICS Corp (UTHR)
Neuromuscular Blocking Agents	UNITED THERAPEUTICS Corp (UTHR)
Universal Donor TGFβi NK Cells	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(2)

Drug	Company
agent-797	MiNK Therapeutics, Inc. (INKT)
iC9.GD2.CAR.IL-15 T-cells	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 6 drugs in development for Respiratory Distress Syndrome, Adult across 2 companies.

There are 3 clinical trials targeting Respiratory Distress Syndrome, Adult tracked by BioSniper.

The estimated prevalence of Respiratory Distress Syndrome, Adult is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.